Xagena.net - Update in Medicine

Results of the Phase III EINSTEIN-DVT study have shown that the oral anticoagulant Rivaroxaban ( Xarelto ) achieved the primary efficacy and safety outcomes in the treatment of patients with acute, symptomatic deep vein thrombosis ( DVT ).

Rivaroxaban has demonstrated non-inferior efficacy in the treatment of deep vein thrombosis compared with initial Enoxaparin ( Clexane, Lovenox ) treatment followed by a vitamin K antagonist, the current standard therapy for the treatment of deep vein thrombosis.
Recurrent symptomatic venous thromboembolism ( ie, the composite of recurrent deep vein thrombosis, non-fatal or fatal pulmonary embolism ) occurred in 2.1% of the Rivaroxaban recipients and 3.0% of the subjects receiving standard therapy ( p